CHDI Foundation, Inc.
17
5
5
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.9%
1 terminated/withdrawn out of 17 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Role: collaborator
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
Role: lead
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Role: collaborator
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Role: collaborator
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Role: lead
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626
Role: lead
Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD
Role: lead
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
Role: lead
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
Role: collaborator
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)
Role: collaborator
Development of Assessments for Later Stage HD
Role: lead
PHysical Activity and Exercise Outcomes in Huntington's Disease
Role: collaborator
FuRST 2.0 Cognitive Pre-testing - Round 2
Role: lead
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
Role: lead
FuRST 2.0 Cognitive Pre-Testing
Role: lead
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.
Role: lead
Cognitive Assessment Battery (CAB) Beta Study
Role: lead
All 17 trials loaded